| Double-strand break toxicity is chromatin context independent A Friskes, L Koob, L Krenning, TM Severson, ES Koeleman, X Vergara, ... Nucleic Acids Research 50 (17), 9930-9947, 2022 | 11 | 2022 |
| Paradoxical activation of oncogenic signaling as a cancer treatment strategy MH Dias, A Friskes, S Wang, JM Fernandes Neto, F van Gemert, ... Cancer Discovery, OF1-OF26, 2024 | 7 | 2024 |
| Perturbations in 3D genome organization can promote acquired drug resistance AG Manjón, SG Manzo, S Prekovic, L Potgeter, T van Schaik, NQ Liu, ... Cell Reports 42 (10), 2023 | 7 | 2023 |
| Unexpected gene activation following CRISPR‐Cas9‐mediated genome editing AG Manjón, S Linder, H Teunissen, A Friskes, W Zwart, E de Wit, ... EMBO reports 23 (2), e53902, 2022 | 6 | 2022 |
| MND1 enables homologous recombination in somatic cells primarily outside the context of replication L Koob, A Friskes, L van Bergen, FM Feringa, B van den Broek, ... Molecular Oncology 17 (7), 1192-1211, 2023 | 1 | 2023 |
| Centriole structural integrity defects are a crucial feature of Hydrolethalus Syndrome A Curinha, Z Huang, T Anglen, MA Strong, CR Gliech, CE Jewett, ... bioRxiv, 2024.03. 06.583733, 2024 | | 2024 |
| OC-0511 Hypoxic tumour cells drive tumour relapse after radiotherapy as revealed by a novel tracing tool A Menegakis, C Vennin, J Ient, R Klompmaker, L Krenning, A Friskes, ... Radiotherapy and Oncology 182, S420-S421, 2023 | | 2023 |
| MND1 enables repair of two-ended DNA double-strand breaks L Koob, A Friskes, L van Bergen, FM Feringa, B van den Broek, ... bioRxiv, 2022.08. 24.505076, 2022 | | 2022 |
| Understanding the molecular mechanisms that control centriole biogenesis A Friskes | | 2018 |
| Setting up a CRISPR/Cas9 screen to identify genes that drive aneuploid cancer proliferation A Friskes Faculty of Science and Engineering, 2017 | | 2017 |
| 4DNA damage-dependent AG Manjón, S Manzo, T van Schaik, A Friskes, H Teunissen, D Hintzen, ... Gene re-activation mechanisms in the context of acquired drug resistance, 83, 0 | | |
Rene H. MedemaThe Netherlands Cancer InstituteVerified email at nki.nl
